Summit Therapeutics (SMMT) Gets a Buy from UBS
UBS analyst David Dai has maintained a Buy rating on Summit Therapeutics (SMMT) with a price target of $33.00, while the shares closed at $18.30. The overall analyst consensus for Summit Therapeutics is a Moderate Buy, with an average price target of $30.82. Dai has an average return of -5.6% and a success rate of 44.44% on his stock recommendations.
In a report released yesterday, David Dai from UBS maintained a Buy rating on Summit Therapeutics, with a price target of $33.00. The company’s shares closed yesterday at $18.30.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Dai covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Telix Pharmaceuticals, and IDEAYA Biosciences. According to TipRanks, Dai has an average return of -5.6% and a 44.44% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Summit Therapeutics with a $30.82 average price target.
